eFFECTOR Therapeutics, Inc. Common Stock
EFTR
EFTR was delisted on the 2nd of July, 2024.
3 hedge funds and large institutions have $4.33K invested in eFFECTOR Therapeutics, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 15 closing their positions.
83% less funds holding
Funds holding: 18 → 3 (-15)
98% less capital invested
Capital invested by funds: $251K → $4.33K (-$247K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 15
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$64.9K |
| 2 |
CG
Carlyle Group
Washington,
District of Columbia
|
-$55.9K |
| 3 |
PA
Parallel Advisors
San Francisco,
California
|
-$19.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$17.9K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$7.42K |
EFTR Hedge Fund Activity: Q3 2024 in Review
3 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Common Stock (EFTR) for Q3 2024, worth a combined $4.33K — down 98% from $251K a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of EFTR and 0 opened new positions — a net loss of 15 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Sabby Management, cutting an estimated $64.9K.
- 3 institutional investors held eFFECTOR Therapeutics, Inc. Common Stock (EFTR) as of Q3 2024, down from 18 in Q2 2024.
- Funds reported $4.33K of eFFECTOR Therapeutics, Inc. Common Stock stock for Q3 2024, down 98% quarter-over-quarter.
- 0 funds opened new eFFECTOR Therapeutics, Inc. Common Stock positions in Q3 2024 and 15 closed out, a net change of -15 holders.
- The largest eFFECTOR Therapeutics, Inc. Common Stock seller in Q3 2024 was Sabby Management, an estimated $64.9K sold.
Based on aggregated 13F filings for Q3 2024.